Kenvue to Showcase New Clinical Data on Skin Longevity, Hydration and Sun Protection at American Academy of Dermatology Association Meeting
Science Behind Iconic Brands, including NEUTROGENA® and AVEENO®, Underscores the Company's Expertise and Commitment to Shaping the Future of Skin Health & Beauty
Kenvue Inc. (NYSE: KVUE) will share new clinical data demonstrating how its iconic brands are leveraging the latest science to shape the future of the Skin Health & Beauty category at the 2025 American Academy of Dermatology (AAD) Annual Meeting, set for March 7-11, 2025 at the Orlando Convention Center in Orlando, Florida.
In findings from the 14 clinical studies detailing new Kenvue scientific research, the Company will present evidence alongside industry experts on the effectiveness of formulations behind iconic brands such as Neutrogena® and Aveeno® in cellular health for skin longevity, superior hydration, and exceptional protection against UVA sun damage. The Company's exhibit floor booth #2503 will also feature immersive and innovative experiences from Neutrogena®, Aveeno®, NeoStrata®, Lubriderm® and Rogaine®.
"Our Skin Health and Beauty brands are at the forefront of next-generation science as high-performance products that are effective in promoting the health and longevity of skin," said Adam Ricciardone, Head of R&D, Global Skin Health & Beauty. "The results of these clinical studies further illustrate our commitment to developing innovative, science-backed experiences for consumers that are recommended by industry experts, and our dedication to shaping a new view of care for Skin Health & Beauty in the future."
New research being presented by Kenvue during AAD found:
- Twice daily use of Neutrogena® Collagen Bank, a facial moisturizer featuring a patented micro-peptide technology to penetrate deep surface layers that support collagen production, including the SPF formulation, in the morning diminished collagen loss during the pre-aging phase. This regimen helps improve skin radiance, fine lines, firmness, texture and elasticity, effectively reducing early signs of aging.1
- Leveraging a technique called the "open sandwich" method, where retinoids are applied either before or after moisturization with Neutrogena® Hydro Boost Water Cream, ensures optimal hydration, especially for those with sensitive skin.2
- Applying an oat-based Aveeno® liquid wash and moisturizer regimen for infants, with products like Aveeno® Baby Eczema Therapy Wash and Aveeno® Baby Eczema Therapy Nighttime Balm, improves hydration, the integrity of the skin barrier, and also enhances the overall quality of life for infants.3 In a separate study, oat flour, a key ingredient across the entire Aveeno® product line, was also found to boost the production of hyaluronic acid (HA) by 43%, a key component for overall skin hydration.4
- Pure mineral sunscreens with a high SPF have variability in effectiveness of UVA protection, premature aging, and aesthetics. New Neutrogena® Ultra Sheer Mineral Face Liquid SPF 70 offers 3x more UVA protection and 30% less whitening versus leading competitors, using an exclusive technology that maximizes the efficacy potential of the UV filters through proper and uniform mineral dispersion.5
More information on all studies being presented at AAD can be found here: https://kenvuepro.com/en-us/events/2025-aad-annual-meeting
About Kenvue
Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers' hands and earn a place in their hearts and homes. Learn more at www.kenvue.com.
Neutrogena®, Aveeno®, NeoStrata®, Lubriderm® and Rogaine® are brands of Kenvue Brands LLC, a subsidiary of Kenvue Inc.
1 Multi-decade Studies of Clinical and Pre-clinical Changes in Facial Skin Define Skin Pre-aging; Shyr, Thomas C., et al.
2 Tretinoin and Retinol Bioactivity are Retained when Layered with Adjunctive Gel-Matrix Moisturizer or a Cream Moisturizer in an "Open Sandwich" Regimen; Parsa, Ramine PhD, et al.
3 Improving Skin Hydration, Barrier Integrity and Quality of Life in Brazilian Babies with Sensitive Skin: A Clinical Study on the use of an Oat-Based Wash and Moisturizer Regimen; Santos, Sarah, et al.
4 Oat Flour Enhances Hyaluronic Acid Secretion Providing Possible Mechanism for Moisturization Effects; Besingi, Richard PhD, et al.
5 Evaluating the Variability in Effective Protection Against Ultraviolet A (UVA) Radiation-Induced Pigmentation Provided by Mineral Sunscreens; Williams, Joshua D., et al.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding data being presented at the American Academy of Dermatologists Annual Meeting. Forward-looking statements may be identified by the use of words such as "plans," "expects," "will," "anticipates," "estimates" and other words of similar meaning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kenvue and its affiliates.
A list and descriptions of risks, uncertainties and other factors can be found in Kenvue's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 29, 2024 and subsequent Quarterly Reports on Form 10-Q and other filings, available at www.kenvue.com or on request from Kenvue. Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250307889299/en/
R&D Media Relations
Lindsay Hymson Schechter
[email protected]